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Abstract
Background: Text mining and data integration methods are gaining ground in the field of health sciences due to
the exponential growth of bio-medical literature and information stored in biological databases. While such
methods mostly try to extract bioentity associations from PubMed, very few of them are dedicated in mining other
types of repositories such as chemical databases.
Results: Herein, we apply a text mining approach on the DrugBank database in order to explore drug associations
based on the DrugBank “Description”, “Indication”, “Pharmacodynamics” and “Mechanism of Action” text fields. We
apply Name Entity Recognition (NER) techniques on these fields to identify chemicals, proteins, genes, pathways,
diseases, and we utilize the TextQuest algorithm to find additional biologically significant words. Using a plethora of
similarity and partitional clustering techniques, we group the DrugBank records based on their common terms and
investigate possible scenarios why these records are clustered together. Different views such as clustered chemicals
based on their textual information, tag clouds consisting of Significant Terms along with the terms that were used
for clustering are delivered to the user through a user-friendly web interface.
Conclusions: DrugQuest is a text mining tool for knowledge discovery: it is designed to cluster DrugBank records
based on text attributes in order to find new associations between drugs. The service is freely available at
http://bioinformatics.med.uoc.gr/drugquest.
Keywords: Drug associations, Chemicals, Data integration, Name entity recognition, Text mining, Document
clustering, Knowledge discovery
Background
The latest advances of next generation sequencing tech-
niques, as well as the rise of the era of personalized medi-
cine, have opened new challenges in the field of
Bioinformatics. Data integration, drug discovery, drug re-
purposing, organization of chemical compound information
in databases, identification of their therapeutic properties
and their side effects along with the discovery of novel asso-
ciations between them still remain active research fields.
There is a plethora of widely used databases that at-
tempt to organize chemical information along with others
which specialize in drug interactions. Herein, we present a
short review of repositories which serve the former pur-
pose. PubChem [1, 2], for example, is a database mainly
composed by PubChem Substance, PubChem Compound,
and PubChem BioAssay and is designed to provide infor-
mation on the biological activities of small molecules.
Today, PubChem hosts information for about 68,369,263
compounds, 196,730,517 substances, 1,154,333 BioAssays,
2,083,054 tested compounds, 3,141,545 tested Substances,
64 RNAi-BioAssays, 228,500,456 BioActivities, 9853 Pro-
tein Targets and 57,039 gene targets. Chemical Entities of
Biological Interest (ChEBI) database [3, 4] is a freely
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available dictionary of molecular entities focused on small
chemical compounds. ChemExper (www.chemexper.com)
is a web based database which contains information about
chemicals and their physical characteristics. ChemExper
can be updated manually as everyone is allowed to submit
new, update existing and retrieve chemical records online.
ChemBank [5] is focused on incorporating small mole-
cules, small-molecule screens and resources towards the
gain of biological and medical insights. It is designed to
aid chemists in synthesizing novel compounds and biolo-
gists in exploring small molecules that perturb specific
biological pathways. Side Effect Resource (SIDER) [6] is a
great collection of marketed medicines along with their
recorded adverse drug reactions and their side effects. At
the moment SIDER holds information about 996 drugs,
4192 side effects and 99,423 drug-side effect pairs. Chem-
Spider (http://www.chemspider.com) is a data integration
platform which comes with a fast indexing/searching of
over 26 million structures from hundreds of data sources.
Its mission is to bring together information from 34 mil-
lion compounds from over 490 data sources, along with
their original source links. Therapeutic Target Database
(TTD) [7] provides information about the known and ex-
plored therapeutic protein and nucleic acid targets, the
targeted disease, pathway information and the corre-
sponding drugs directed at each of these targets. This
database currently contains 2025 targets (364 successful,
286 clinical trials and 1331 research targets) and 17,816
drugs (1540 approved, 1423 clinical trials, 14,853 experi-
mental drugs and 3681 multi-target agents, 14,170 small
molecules and 652 antisense drugs with available structure
or oligonucleotide sequence). Targets and drugs in this
database cover 61 protein biochemical classes and 140
drug therapeutic classes respectively. SuperTarget/Mata-
dor [8] is designed to give answers to complex queries
such as finding drugs that are metabolized by the same
enzyme, drugs that target a certain metabolic pathway or
even drugs that target the same protein but are metabo-
lized by different enzymes. The scenarios are based on in-
formation about medical indication areas, adverse side
effects and drug metabolism. Currently, the database con-
tains more than 2500 target proteins, which are annotated
with about 7300 relations to 1500 drugs. Finally, Super-
Drug [9] contains approximately 2500 chemical structures
of active ingredients of essential marketed drugs. At the
moment, it contains 2.396 compounds with 108.198
conformers.
In this article, we focus on the DrugBank [10–12]
repository which is a freely available resource that
combines detailed information about 7736 drug en-
tries including 1584 FDA-approved small molecule
drugs, 158 FDA-approved biotech (protein/peptide)
drugs, 89 nutraceuticals and over 6000 experimental
drugs. For each drug, information about taxonomy,
pharmacology, pharmacoeconomics, chemical proper-
ties, related literature and other chemical interactors
can be retrieved along with information about its
targeted proteins.
DrugQuest clusters DrugBank records based on their
textual information in a multidimensional vector space.
We mainly apply partitional clustering algorithms in
order to group together DrugBank records based on
their textual information. Toxicity, targeted pathways,
targeted proteins, diseases and/or other interactors are
few examples of such textual information. Uniquely
assigning DrugBank records into clusters, based on
tagged terms such as pathways diseases, molecules, bio-
logical processes, can make DrugQuest a promising tool
for new concept discovery and detection of new drug
associations. The platform is available at http://bioinfor
matics.med.uoc.gr/drugquest.
Methods
An overview of DrugQuest’s workflow in steps
The workflow of DrugQuest is summarized below in ten
steps and presented analytically in Fig. 1.
1) The user provides a query (keyword matching using
Boolean operators).
2) Selection of relevant DrugBank records upon query
based on the “Description”, “Indication”,
“Pharmacodynamics” and “Mechanism of Action” fields
of the DrugBank records.
3) Retrieval of textual entries of the drug records from
the local database, where DrugBank is stored.
4) Collection of tagged terms for each record. Notably,
the tagging of the whole DrugBank repository has been
performed beforehand, in order to avoid unnecessary
bottlenecks for the user. DrugQuest uses the Reflect
tagging service [13] to identify proteins and chemicals
and the BeCAS tagging service for diseases/disorders
and pathways identification.
5) Calculation of the TF-IDF score (Term Frequency x
Inverse Document Frequency) for each of non-tagged
words in the textual corpus to determine its
‘importance’.
6) Removal of English words with low TF-IDF values
based on the British National Corpus (BNC -
http://www.natcorp.ox.ac.uk/), a collection of sam-
ples of written and spoken language from a wide
range of sources, accompanied by the respective
word frequencies, designed to represent a wide
cross-section of British English, both spoken and
written, from the late twentieth century.
7) Removal of words belonging to a custom designed
“stop word list” with common English words,
such as articles and prepositions. The remaining
words, after steps (4) - (7) will be characteristic
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for each abstract and will be referred as
“Significant Terms”.
8) Creation of binary vectors representing each DrugBank
record, indicating the presence or absence of
Significant Terms and of tagged terms representing
proteins, chemicals, diseases and pathways. In these
vectors, the TF-IDF value is not taken into account.
9) Document clustering is performed with a user-defined
combination of metric-clustering algorithm (selected
among different available options).
10) Annotated representations and visualization of the
results in two forms i.e. “Tag Clouds” and “Clustered
Drugs” allow user to detect which of the terms belong
to the four tagging categories.
Fig. 1 DrugQuest’s workflow. a Queries to DrugBank and retrieval of records related to the query. b DrugBank record mining based on textual information
such as: description, toxicology and pharmacology. c Name Entity Recognition techniques to identify genes/proteins, chemicals, diseases, pathways. d
TextQuest algorithm to identify non tagged Significant Terms. e Partitional clustering of DrugBank records using various clustering algorithms and similarity
measures. f Visual representation of results: Left: Tag cloud example of highly representative terms per cluster. Right: DrugBank records assigned to clusters
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Query system
DrugQuest is a freely available, easy-to use web application
which mines the DrugBank repository and clusters its re-
cords based on their textual information towards the dis-
covery of new drug associations. It comes with a user
friendly Google-like interface where one can query for a
symptom (i.e. “pain”, “headache” etc.) and retrieve the rele-
vant to the query DrugBank records. Notably, DrugQuest’s
query system at the moment allows for simple keyword
string matching within the textual information of each
DrugBank record. Users can choose between simple Bool-
ean operators (‘OR’ for any query term and ‘AND’ for all
query terms). As each DrugBank record consists of various
fields, we selected for fields with a high textual information
content, more particularly: “Description”, “Indication”,
“Pharmacodynamics” and “Mechanism of Action”.
Automated identification of terms
Named Entity Recognition techniques have been applied
on the locally stored and parsed DrugBank (version 4.2) re-
pository. To minimize the gene/protein and chemical dis-
ambiguation problem and cope with the complexity of
multiple synonyms, we link synonymous terms to unique
database identifiers by utilizing the Reflect tagging service
[13]. Similarly, for diseases and pathways we utilized the
BeCAS tagging service [14]. This way, gene and protein
names are mapped to ENSEMBL identifiers, drug/chemical
names to PubChem [1, 2], diseases/disorders to a subset
of UMLS [15] and pathways to the NCBI BioSystems re-
pository [16]. Prior to using the tagged terms identified by
both tagger, we manually checked for redundancies and
inconsistencies.
In order to take advantage of the remaining untagged
text, we utilize the TextQuest algorithm [17] to identify bio-
logically significant words. Such words may refer to a
phenomenon or a biological process or a function and
might be worthy of attention. Shortly, the TextQuest algo-
rithm initially calculates the TF-IDF score (Term Frequency
x Inverse Document Frequency) for each word in the cor-
pus to determine its ‘significance’. Then it removes the
words with low TF-IDF scores and words belonging to a
custom designed “stop word list” with common English
words, such as articles and prepositions. The remaining
words are characteristic for each abstract and we treat them
as ‘Significant Terms’.
Ideally, a tagger should identify all synonyms and re-
direct them to the same database record. In the very rare
cases where this does not occur, two synonyms may both
appear as Significant Terms.
Document clustering
Prior to partitional clustering, we represent each DrugBank
record with a binary vector holding the presences and the
absences of the tagged and the other/remaining biologically
significant terms (not captured by the taggers) that were
found in the text collection. Similarity metrics such as
Tanimoto coefficient, Pearson coefficient or simple cosine
similarity are then calculated in order to construct an all-
against-all similarity matrix between the retrieved Drug-
Bank records, relevant to a query. Based on this similarity
matrix, we subsequently apply a partitional algorithm
(among several algorithms that are available) to group the
retrieved records and assign them to distinct clusters based
on their textual information. At the moment, a plethora of
clustering algorithms such as Affinity Propagation [18],
MCL [19], k-Means [20], average linkage hierarchical
clustering from SCPS [21] and spectral [22] clustering
algorithms can be used.
Representation of results and on-the-fly data integration
DrugQuest delivers different views of the results organized
under tabs, along with a frame holding a summary of the
analysis. The “Tag Clouds” view displays a tag-cloud of the
Significant Terms that characterize each document cluster.
The font size of each text is proportional to the frequency
of the term in the respective cluster and, therefore, the big-
ger the size, the more over-represented the term. More spe-
cifically, the font size of each Significant Term is
proportional to the number of records of each cluster in
which the term appears. Terms that do not appear very
often (based on an empirically chosen TF-IDF threshold of
19) in each cluster are not shown in order to present a less
‘cluttered’ and more user-friendly cluster. In this view, users
can highlight terms that are unique for a cluster as well as
tagged genes/proteins, chemicals, pathways, diseases and
terms that are not standard English terms (i.e. they do not
belong in the reference English dictionary). The “Clustered
Drugs” tab categorizes the DrugBank records in subjects
corresponding to implicit concepts accompanied with a link
to the respective DrugBank record.
Implementation and running time
DrugBank repository is stored locally in a MySQL database.
The web interface is written with the use of CGI, Perl and
Javascript. The MCL algorithm is written in C while the
rest of the clustering algorithms in Java taken from the
jClust java application [23]. Finally, vector similarities are
calculated with the use of R package [24]. As DrugQuest
has a limit of 5000 textual records per analysis, the running
time complexity of the algorithms is not an issue. More-
over, due DrugBank’s small size, each query normally lasts
few seconds to process.
Results
Pharmacological exploitation of DrugQuest usefulness
through the example of the term ‘aspirin’
Aspirin (acetylsalicylic acid) is one of the most widely used
drugs, since it has been in the market for more than
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100 years (first synthesis and clinical trial in 1897–1899).
Aspirin belongs to the pharmacological class of non-
steroidal anti-inflammatory drugs (NSAIDs). The pharma-
cological mechanism of action of aspirin is mediated
through the inhibition of both cyclooxygenases 1 and 2
(COX-1, COX-2), thus decreasing pain, fever, and inflam-
mation. Interestingly, besides its well-known analgesic,
antipyretic and anti-inflammatory activity, aspirin also ex-
erts anticoagulant effects by inhibiting platelet aggrega-
tion. The favorable response of aspirin in reducing fever is
mediated through the inhibition of prostaglandin E2
(PGE2) synthesis. A more recently developed class of
NSAIDs is that of COX-2 specific inhibitors, such as cele-
coxib [25–28].
In the following example, by querying for “aspirin” in
DrugQuest and using the MCL clustering algorithm with
inflation value 3, the pharmacological usefulness of this
text-mining biomedical suite is clearly displayed. The
MCL algorithm calculates automatically the number of
clusters, i.e. the user does not provide a preference bias
for the number of clusters. As shown in Fig. 2, four clus-
ters have been recovered. The analysis of tags grouped
in each cluster revealed that: a) Cluster 1 consists of i)
tags focusing on the anticoagulant blood effects of
Fig. 2 Aspirin Example. Tag Cloud view for term “aspirin” related query. Cluster 1: tags focusing on the anticoagulant blood effects of aspirin in
related diseases including other anticoagulant drug classes along with analgesic, antipyretic and anti-inflammatory activities of aspirin. Cluster 2:
tags refer to combination therapy of aspirin with other pharmacological classes of drugs. Cluster 3: tags propose combination therapy of aspirin
with other analgesic drugs for the relief of pain in severe conditions. Cluster 4: tags point to a specific disease where aspirin is included in the
therapeutic protocol, e.g. heart diseases
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aspirin in related diseases including other anticoagulant
drug classes (tags: platelets, antiplatelet, thromboxane,
glycoprotein, GPIIb/IIIa, IIb/IIIa, fibrinogen, endothelial,
vascular disease, ischemic) and ii) analgesic, antipyretic
and anti-inflammatory activities of aspirin as well as the
related diseases and other classes of relevant drugs (tags:
prostaglandin, anti-inflammatory, Cox-1, COX-2, non-
steroidal, NSAIDs, NSAID, analgesic, antipyretic,
rheumatoid arthritis, arachidonic acid, cyclooxygenase(s),
cyclooxygenase, juvenile rheumatoid arthritis, osteoarth-
ritis); b) Cluster 2 tags refer to combination therapy of
aspirin with other pharmacological classes of drugs (tags:
barbiturate(s), caffeine, CNS, GABA, GABAA, headaches,
migraines, mood alteration, sedative, depressants, thal-
amus). For example, as shown in DrugBank, “Butalbital
is often combined with other medications, such as acet-
aminophen or aspirin, and is commonly prescribed for
the treatment of pain and headache…Methylphenobarbi-
tal … and thiamylal are barbiturates …. often combined
with aspirin”; c) Cluster 3 tags propose combination
therapy of aspirin with other analgesic drugs for the re-
lief of pain in severe conditions (tags: oxycodone, coma,
codeine, hydrocodone, addicting, opiods, narcotic, pain,
severe pain, CNS, 3-methoxy-17-methylmorphinan). For
example, as shown in DrugBank, “Oxycodone… and
hydrocodone are narcotic analgesics … often combined
with aspirin”. d) Cluster 4 tags point to a specific disease
where aspirin is included in the therapeutic protocol,
e.g. heart diseases (tags: angina pectoris, anticoagulant,
antithrombin, anti-Xa, clotting, embolisms, heparins, in-
duced thrombocytopenia, ischemic, LMWH, low molecu-
lar weight heparin, myocardial infractions, prothrombin,
thrombin, thrombosis, thromboplastin, unstable angina
pectoris, venous thrombosis).
Overall, the classification of knowledge related to ‘as-
pirin’ by DrugQuest in these 4 clusters corresponds to the
various levels of the existing pharmacological information
for this old drug. Importantly, this information is appro-
priately categorized providing an overview of the drug in a
way that could be useful for both research and educational
purposes to healthcare practitioners, healthcare policy
makers, regulatory agencies and pharmacologists.
Detecting drugs belonging to the pharmacological class
of selective serotonin-reuptake inhibitors (SSRIs)
Antidepressant drugs belonging to the class of selective
serotonin-reuptake inhibitors (SSRIs) are used as an add-
itional case study to further exemplify the usefulness of
DrugQuest. In particular, very similar SSRI drugs such
as citalopram, fluoxetine, paroxetine and sertraline were
compared to each other in order to pinpoint differences
and similarities. According to DrugBank, despite SSRIs
act as potent inhibitors of neuronal serotonin re-uptake,
they do not substantially affect norepinephrine or
dopamine reuptake nor do they antagonize α- or β- ad-
renergic, dopamine D2 or histamine H1 receptors. In this
manner, SSRIs affect somatodendritic 5-HT1A and ter-
minal autoreceptors that subsequently lead to adaptive
changes in neuronal function, thus leading to enhanced
serotonergic neurotransmission. Moreover, the clinical
use of SSRIs can lead to the emergence of adverse drug
reactions (ADRs), like dry mouth, nausea, dizziness,
drowsiness, sexual dysfunction and headache [29–32].
As shown in Fig. 3, by querying for each of the aforemen-
tioned drugs and using the MCL algorithm, DrugQuest
produced one cluster with Significant Terms for each of
them. By inspecting the tag content of the relevant clusters
we clearly observe two traits: i) common tags characterizing
the class of SSRIs (in terms of pharmacological effects,
ADRs, and/or clinical uses) appear in all four clusters (5-
HT, CYP, adrenergic, antidepressant, autoreceptors, CNS,
desensitization, dopamine, drowsiness, D2, headaches, hista-
mine, H1, irritable bowel, nausea, OCD, panic disorder,
MDD, premature ejaculation, premenstrual dysphoric dis-
order, PTSD, reuptake, serotonergic, serotonin, sexual dys-
function, somatodendritic, SSRIs, tremors, vertigo, watery
stools, xerostomia). ii) tags related to specific pharmaco-
logical, chemical or clinical properties of each individual
drug appearing in each respective cluster. The Citalopram
cluster is uniquely characterized by the terms DCT, antibu-
limic, benzodiazepine, dysmorphic disorder, coma, convul-
sions, GABA, monoamine, mood disorders, oxidase, sinus
tachycardia. Similarly, the Fluoxetine cluster is uniquely
characterized by the terms 1,2,4-triazole, Benzene, bulimia
nervosa, chlorobenzene, diazinane, flu-like symptoms, in-
fluenza, loss of appetite, low libido, skin rashes. In the Par-
oxetine cluster, the terms Arthritis, rheumatoid arthritis
are over-represented whereas in the Sertraline cluster, the
terms flushing, hot flush are highlighted.
Discussion
DrugQuest is a concept discovery tool mainly designed
for finding new associations between known drugs but
also for providing concise summation of a large corpus
of drug-related knowledge. It uses textual information
related to a drug and allows clustering algorithms to
group chemicals based on this information. As it is
chemically oriented, it differs significantly from its sister
project BioTextQuest [33, 34], which is mainly devel-
oped to mine PubMed and cluster PubMed documents
into topics. Among others, one of the main differences
is that DrugQuest additionally uses tagging services at
the back-end to cope with the complexity of multiple
synonyms and chemical disambiguation, a feature that is
missing in the BioTextQuest application.
To our experience and from a text mining point of
view, chemical databases are peculiar in terms of the ter-
minology and the vocabulary used, and small name
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changes may refer to completely different molecules
with different properties and characteristics. Therefore,
pre-defined tagging services were necessary to spot such
details as opposed to BioTextQuest that mines textual
corpuses more freely.
Despite the fact that the gene/protein annotation pro-
vided by the Reflect API and the Reflect Web Service
[13] can vary, probably due to the backend dictionary
updates, we insisted in using the API to pre-annotate
the whole DrugBank. This allowed us to avoid invoking
the external Reflect Web Service on the fly, sidestep-
ping any Reflect Web Service downtime and time
bottlenecks.
DrugQuest currently mines the DrugBank repository,
but we aim to integrate other repositories like the ones
mentioned in the introductory section (PubChem,
Fig. 3 SSRIs Example. Tag Cloud view for drugs “citalopram”, “fluoxetine”, “paroxetine” and “sertraline”. Orange: common tags characterizing the
class of SSRIs (in terms of pharmacological effects, ADRs, and/or clinical uses). Blue: tags related to specific pharmacological, chemical or clinical
properties of each individual drug appearing in each respective cluster
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ChEBI, SuperTarget/Matador etc.). Notably, we chose to
start with the DrugBank database because of its smaller
size, a fact that renders it easier for parsing. It is well
maintained and many records are manually curated
while it is frequently referenced by other resources.
Overall, we believe that the philosophy of DrugQuest
could be a promising approach and a good starting point
in mining chemical-related repositories and can boost
the extraction of new knowledge by bringing unobserved
drug repurposing and drug repositioning scenarios on
the surface.
Conclusions
DrugQuest is a web application that utilizes state-of-the-
art text mining methodologies, name entity recognition
techniques and data-integration approaches to mine the
DrugBank repository and group chemicals/drugs based
on their textual information.
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